Neurofibromatosis type 1 (NF1) is a genetic condition that causes changes in skin pigment and growth of mostly noncancerous tumors along nerves, and it affects the skin, nervous system, bones, and sometimes the eyes. You should know that NF1 stems from a mutation in the NF1 gene and can vary widely in severity, so early diagnosis and coordinated care matter for managing symptoms and reducing complications.
This article What Is NF1 Neurofibromatosis will explain how the condition is inherited and diagnosed, what signs and symptoms to watch for, and how clinicians approach monitoring and treatment so you can understand practical steps for care and decision-making.
Genetic Background and Diagnosis
You will learn what causes NF1, how it passes in families, and the main ways clinicians confirm the diagnosis using physical criteria and genetic testing.
Causes and Inheritance Patterns
NF1 results from pathogenic variants in the NF1 gene on chromosome 17, which encodes neurofibromin, a protein that helps regulate cell growth. Loss or dysfunction of neurofibromin increases cell proliferation, raising the risk of benign and malignant nerve-sheath tumors.
About half of people with NF1 inherit the variant in an autosomal dominant pattern, so each child of an affected parent has a 50% chance of inheriting the change. The other half arise from new (de novo) mutations that occur in the affected individual. Mosaic or segmental NF1 occurs when a post‑zygotic mutation affects only part of the body; standard inheritance risks differ in mosaic cases and depend on whether germ cells carry the variant.
You should discuss family history and consider targeted testing if multiple relatives show café‑au‑lait spots, neurofibromas, or known NF1 variants.
Key Diagnostic Criteria
Diagnosis of NF1 relies on clinical features and can be confirmed by genetic testing. Clinicians commonly use established diagnostic criteria that include multiple café‑au‑lait macules, two or more neurofibromas or one plexiform neurofibroma, axillary/inguinal freckling, Lisch nodules (iris hamartomas), specific bony lesions, optic pathway glioma, and a pathogenic NF1 variant in the individual or a first‑degree relative.
If you meet two or more clinical criteria, a clinician often makes a clinical diagnosis without immediate genetic testing. Eye exams and dermatologic and neurologic assessments are standard. Imaging (MRI) is used to evaluate suspected plexiform tumors or optic pathway gliomas. Use of standardized checklists improves diagnostic consistency across ages, since some features appear later in childhood.
Recent Advances in Genetic Testing
Genetic testing for NF1 has improved sensitivity and specificity through next‑generation sequencing (NGS) panels and combined methods. You can get sequence analysis to detect single‑nucleotide variants and small indels, plus deletion/duplication testing (MLPA or copy‑number analysis) to find larger NF1 gene rearrangements.
For suspected mosaic NF1, testing may require sequencing of affected tissue (skin or tumor) in addition to blood, because blood testing can miss low‑level mosaicism. Somatic mosaicism detection has improved with deep sequencing and bioinformatic pipelines that identify low‑frequency variants. Prenatal and preimplantation genetic testing are options when a familial NF1 variant is known; genetic counseling is strongly recommended to interpret results and discuss reproductive choices.
Clinical Manifestations and Management
NF1 affects skin, nerves, bones, and learning. It requires periodic monitoring, targeted symptom treatment, and coordination among specialists.
Common Physical Features
You will often first notice multiple café-au-lait macules—flat, light-brown skin spots—present from infancy. Having six or more café-au-lait spots greater than 5 mm in young children or 15 mm in older children is a clinical diagnostic marker.
Cutaneous neurofibromas appear as soft, skin-colored nodules that increase with age and can cause disfigurement or local pain. Plexiform neurofibromas are larger, deeper nerve tumors present in about 20–30% of people with NF1 and can cause functional impairment, compression of nearby structures, or significant growth requiring intervention.
Other visible signs include axillary/inguinal freckling and Lisch nodules (iris hamartomas) detectable on slit-lamp eye exam. Skeletal findings—scoliosis, tibial pseudarthrosis, and short stature—occur in a subset and may require orthopedic management.
Neurological and Cognitive Impacts
You may experience learning disabilities, attention-deficit/hyperactivity disorder (ADHD), and delays in language or executive function; these are common and often require educational support. Intelligence ranges widely; many people have normal IQ but still need individualized education plans and behavioral therapies.
Seizures and headaches, including migraine, occur more frequently than in the general population and should prompt neurologic evaluation. Optic pathway gliomas, typically arising in early childhood, can impair vision and require serial ophthalmologic and neuroimaging surveillance.
Pain and peripheral neuropathy from neurofibromas or plexiform tumors can limit daily activities. Referral to neurology, pain specialists, and neuropsychology helps tailor cognitive, behavioral, and symptomatic therapies.
Available Treatment Approaches
Management focuses on surveillance, symptomatic care, and targeted therapies. You should receive regular exams: dermatologic and neurologic checks, annual blood pressure measurements, ophthalmology visits in childhood, and MR imaging when clinically indicated.
Surgery remains the primary option for symptomatic or disfiguring tumors, but complete resection may be limited by tumor infiltration of nerves. For inoperable plexiform neurofibromas, MEK inhibitors (for example, selumetinib) have demonstrated tumor shrinkage and symptomatic benefit in children and some adults.
Pain is managed with multimodal approaches—NSAIDs, neuropathic agents, procedural interventions, and physical therapy. Educational and behavioral therapies address learning and attention issues. Genetic counseling is essential for family planning; molecular testing can confirm diagnosis or clarify atypical presentations.
Long-Term Prognosis
Your long-term outlook depends on specific complications: tumor burden, optic pathway involvement, vascular lesions, and skeletal deformities largely determine morbidity. Life expectancy is reduced in some cohorts due to malignant transformation (malignant peripheral nerve sheath tumor) and vascular complications, but outcomes vary widely.
Regular surveillance improves early detection of progressive tumors and treatable complications. Advances in targeted therapies and multidisciplinary care have expanded options, especially for symptomatic plexiform neurofibromas. You should work with a coordinated care team to monitor disease progression and address quality-of-life issues as they arise.
